Fair Value Measurements and Financial Instruments

6 Months Ended

Jun. 30, 2013

Fair Value Measurements and Financial Instruments

Note 17—Fair value measurements and financial instruments:

The following table summarizes the valuation of our marketable securities, financial instruments and other items recorded on a fair value basis as of:

	Fair Value Measurements
	Total			Quoted Pricesin Active Markets (Level 1)				Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)
	(In millions)
Asset (liability)
December31, 2012:
Marketable securities:
Current	$	.9			$	—			$	.9		$	—
Noncurrent		256.8				3.5				3.3			250.0
Currency forward contracts		1.8				1.8				—			—
June30, 2013:
Marketable securities:
Current	$	1.6			$	—			$	1.6		$	—
Noncurrent		254.1				1.9				2.2			250.0
Currency forward contracts		(2.0	)			(2.0	)			—			—

See Note 4 for information on how we determine fair value of our noncurrent marketable securities.

Certain of our Chemicals Segment’s sales generated by its non-U.S. operations are denominated in U.S. dollars. Our Chemicals Segment periodically uses currency forward contracts to manage a very nominal portion of currency exchange rate risk associated with trade receivables denominated in a currency other than the holder’s functional currency or similar exchange rate risk associated with future sales. We have not entered into these contracts for trading or speculative purposes in the past, nor do we currently anticipate entering into such contracts for trading or speculative purposes in the future. Derivatives used to hedge forecasted transactions and specific cash flows associated with financial assets and liabilities denominated in currencies other than the U.S. dollar and which meet the criteria for hedge accounting are designated as cash flow hedges. Consequently, the effective portion of gains and losses is deferred as a component of accumulated other comprehensive income and is recognized in earnings at the time the hedged item affects earnings. Contracts that do not meet the criteria for hedge accounting are marked-to-market at each balance sheet date with any resulting gain or loss recognized in income currently as part of net currency transactions. The fair value of the currency forward contracts is determined using Level 1 inputs based on the currency spot forward rates quoted by banks or currency dealers.

At June30, 2013, our Chemicals Segment had currency forward contracts to exchange:

an aggregate of $54.0 million for an equivalent value of Canadian dollars at exchange ratesranging from Cdn. $1.02 to Cdn. $1.06 per U.S. dollar. These contracts with Wells Fargo Bank, N.A. mature from July 2013 through December 2014 at a rate of $3.0 million per month, subject to early redemption provisions at our option;

an aggregate $35.0 million for an equivalent value of Norwegian kroner at exchange rates ranging from kroner 5.84 to kroner 6.14per U.S. dollar. These contracts with DnB Nor Bank ASA mature at a rate of $5.0 million per month in certain months from August 2013 through April 2014; and

an aggregate €22.0million for an equivalent value of Norwegian kroner at exchange rates ranging from kroner 7.50 to kroner 8.07per euro. These contracts with DnBNor Bank ASA mature at a rate of €2.0million to €5.0 million per month in certain months from July 2013 through April 2014.

The estimated fair value of our currency forward contracts at June30, 2013 was a net liability of $2.0 million, of which $.3 million is recognized as part of accounts and other receivables and $2.3 million is recognized as part of accounts payable and accrued liabilities. There is also a corresponding $2.0 million currency transaction loss recognized in our Condensed Consolidated Statement of Operations. Our Chemicals Segment is not currently using hedge accounting for its outstanding currency forward contracts at June30, 2013, and it did not use hedge accounting for any of such contracts previously held in 2012.

The following table presents the financial instruments that are not carried at fair value but which require fair value disclosure:

	December31, 2012				June30,2013
	Carrying amount		Fair value		Carrying amount			Fair value
	(In millions)
Cash, cash equivalents and restricted cash equivalents	$	395.9	$	395.9		$	208.1		$	208.1
Long-term debt (excluding capitalized leases):
Kronos note payable to Contran	$	—	$	—		$	180.0		$	180.0
Kronos term loan		384.5		396.8			98.6			100.4
Snake River Sugar Company fixed rate loans		250.0		250.0			250.0			250.0
WCS fixed rate debt		77.1		77.1			76.4			76.4
Valhi credit facility with Contran		157.6		157.6			159.7			159.7
Kronos variable rate bank credit facility		13.2		13.2			26.1			26.1
CompX variable rate promissory note		18.5		18.5			18.0			18.0
Noncontrolling interest in:
Kronos common stock	$	267.0	$	442.6		$	242.2		$	368.7
NL common stock		77.8		94.8			74.4			93.6
CompX common stock		13.3		23.4			13.4			22.9
Valhi stockholders’ equity	$	733.6	$	4,238.9		$	606.9		$	4,659.5

The fair value of our publicly-traded marketable securities, noncontrolling interest in NL, Kronos and CompX and our common stockholders’ equity are all based upon quoted market prices, Level 1 inputs at each balance sheet date. At December31, 2012 and June30, 2013, the estimated market price of Kronos’ term loan was $1,017.5 per $1,000 principal amount and $1,004.4 per $1,000 principal amount, respectively. The fair value of Kronos’ term loan was based on quoted market prices; however, these quoted market prices represent Level 2 inputs because the markets in which the term loan trades were not active. The fair value of our fixed-rate nonrecourse loans from Snake River Sugar Company is based upon the $250 million redemption price of our investment in Amalgamated, which collateralizes the nonrecourse loans (this is a Level 3 input). Fair value variable interest debt and other fixed-rate debt are deemed to approximate book value, which represents Level 2 inputs. Due to their near-term maturities, the carrying amounts of accounts receivable and accounts payable are considered equivalent to fair value. See Notes 5 and 8.